Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
48.09
-0.02 (-0.04%)
Streaming Delayed Price
Updated: 11:42 AM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
Today 6:59 EDT
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
August 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
August 20, 2024
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
August 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
MarketBeat Week in Review – 7/29 - 8/2
August 03, 2024
The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Pharma Giant's Shares Up After Impressive Q2 Earnings Release
July 29, 2024
Bristol-Myers Squibb shares were up big on the day of its earnings release. The company beat adjusted EPS estimates and saw strong growth from many drugs.
Via
MarketBeat
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
July 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
July 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
July 08, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
June 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
June 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
June 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
June 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
June 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
3 High-Yield Dividend Stocks for Income Now and Growth Later
June 14, 2024
Buying high-yield dividend stocks at a low price today gives you current income with the opportunity for growth when interest rates come down later this year
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
June 13, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
June 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
May 30, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
May 29, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
May 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
May 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
May 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign
May 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
May 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.